Dilated Cardiomyopathy Therapeutics Market
Dilated Cardiomyopathy Therapeutics Market [Drug Class: Aldosterone Antagonists, Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs) and Beta-Blockers] - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
Press Release :
Dilated cardiomyopathy (DCM) is a significant cause of heart failure and a leading indication for heart transplant among children and adults across the globe. This condition is characterized by enlargement of ventricular chamber, thinning of heart walls and inability to sufficiently pump blood throughout the body. Dilated cardiomyopathy can develop at any age but is more common among people aged between 20 years to 60 years. Genetic inheritance is found to affect about 30% to 40% of the total DCM patients. Single gene mutations in either the structural proteins of the myocyte, such as dystrophin, metavinculin, and lamin, or of mitochondrial DNA are also a prominent cause of DCM. Other factors such as diabetes, thyroid disorder, alcoholism, viral infections of the heart and heart valve abnormalities can also lead to dilated cardiomyopathy. Moreover, according to the Pediatric Cardiomyopathy Registry, DCM occurs at a rate of 6 per million children. It is commonly diagnosed in younger children with an average age of diagnosis at 2 years.
The global dilated cardiomyopathy therapeutics market is studied from two perspectives i.e. by drug class and by geography. Till date, there is no FDA approved drug specifically for dilated cardiomyopathy treatment. Owing to the aforementioned fact, the drug classes used in treatment of dilated cardiomyopathy are essentially the same as that for treatment of congestive heart failure. Some of the widely prescribed drug classes in dilated cardiomyopathy treatment encompass aldosterone antagonists, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) and beta blockers. Angiotensin II receptor blockers acquired the largest market share by revenue in 2013, followed by beta blockers. This is attributed to high demand for block buster drugs in dilated cardiomyopathy treatment especially in the developed regions such as North America and Europe. Aldosterone antagonists recorded high growth rate due to the identified positive impact of aldosterone antagonists when used in combination with either ARBs or ACE inhibitors in reducing the progression of Duchenne muscular dystrophy (DMD). Approval for this indication would further accelerate the overall sales of aldosterone antagonists, which in turn would positively impact market growth.
Rising incidences of congestive heart failure across the globe is a prominent growth driver for dilated cardiomyopathy therapeutics market as DCM is one of the leading causes of heart failure. Globally, dilated cardiomyopathy accounts for approximately 30% to 40% of the total congestive heart failure cases each year. Owing to the alarming rise in incidences of congestive heart failure, several companies have initiated clinical trial studies to develop therapeutics specifically for dilated cardiomyopathy. For instance, Array BioPharma in 2015 is conducting a phase II study for its drug candidate ARRY-371797 for DCM treatment. Additionally, Celladon Corporation in 2014 completed its phase II study of MYDICAR for dilated cardiomyopathy treatment. Success of these clinical studies will boost the growth and demand for dilated cardiomyopathy therapeutics market in forthcoming years. However, promising gene therapy and availability of implantable devices (implantable cardioverter defibrillators (ICDs), heart pumps and pacemakers) are major restraints to the DCM therapeutics market.
Geographically, dilated cardiomyopathy therapeutics market is studied for four regions: North America, Europe, Asia Pacific and the Rest of the World. In terms of revenue, North America accounted for the largest market share in 2013 owing to rising incidences of congestive heart failure and high acceptance of branded drugs. In the U.S., DCM is prevalent in approximately five to eight people out of every 100,000 people. In Canada, heart failure affects over 1% of the total population and is responsible for about 9% of all the deaths. Asia Pacific and Rest of the World markets are the fastest growing markets due to rising economic standards, growing disposable income and high demand for generic drugs. Key players in the global DCM market include Array BioPharma, Inc., AstraZeneca plc, Celladon Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and Vericel Corporation.
Dilated cardiomyopathy is an important cause of heart failure and is one of the leading indications for heart transplantation across the globe. It is characterized by the enlargement of ventricular chamber along with systolic dysfunction. Dilated cardiomyopathy can develop at any age but it is more common among people aged between 20 years and 60 years. According to American Society for Clinical Investigation about 25% - 50% of the total dilated cardiomyopathy cases are genetically caused, owing to mutation in genes encoding for cytoskeleton, contractile, or other proteins in myocardial cells.
The global dilated cardiomyopathy therapeutics market is studied in this report from three perspectives: by drug class, by pipelined products and by geography. Dilated cardiomyopathy therapeutics market by drug class encompasses aldosterone antagonists, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) and beta-blockers. A detailed market analysis and forecast for each of these segments have been provided in this study, in terms of market revenue (USD million) for the period 2012 to 2020. The report also provides the compounded annual growth rate (CAGR %) for each of these segments for the forecast period from 2014 to 2020, considering 2012 and 2013 as base years. Geographic regions analyzed for this market include North America, Europe, Asia Pacific and Rest of the World. The North American market comprises the United States and Canada. The European market includes countries such as the U.K., Germany, Italy, and Spain that majorly contribute towards the growth of this region. Similarly, the Asia Pacific market primarily considers India, China, Japan, Singapore, and Australia, along with other smaller markets.
The market overview section of the report demonstrates the major factors determining the market dynamics such as drivers, restraints and opportunities that influence the current as well as future status of this industry. The market overview section of the report also includes qualitative and quantitative analysis of the competitive landscape covering market share analysis by key players.
The study also suggests a list of recommendations which would be useful for existing and future market players in decision making for business growth. Pipeline analysis (Phase I and Phase II) for dilated cardiomyopathy therapeutics market has also been covered in the report. The report concludes with the company profiles section, which illustrates key information about the major players in this market such as company overview, financial overview, product portfolio, business strategies and recent developments. Key players profiled in the report include Array BioPharma, Inc., AstraZeneca plc, Celladon Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd, and Vericel Corporation.
The global dilated cardiomyopathy therapeutics market is segmented into the following categories:
Dilated cardiomyopathy therapeutics market, by drug class
- Aldosterone antagonists
- Angiotensin-converting enzyme (ACE) inhibitors
- Angiotensin II receptor blockers (ARBs)
Dilated cardiomyopathy therapeutics market, by pipeline drugs
Dilated cardiomyopathy therapeutics market, by geography
- North America
- Asia Pacific
- Rest of the World (RoW)